Db therapies contributed to the uptick following the acquisition of Regeneron Pharmaceuticals
main sockets Regeneron Pharmaceuticals has agreed to buy Db Therapeutics for $213 million. DBA shareholders will receive $4 per share when the deal closes, with a potential $3.50 per share later. The best db filter drug treats some cases of hearing loss in children. Shares of Decibel Therapeutics (DBTX) rose more than 75% in early…
